Form 4: Alto Neuroscience COO Michael Hanley Jr. Reports Stock Option Grant

Michael Hanley Jr., COO of Alto Neuroscience, reported the acquisition of stock options for 188,000 shares of common stock.

Summary

• Michael Hanley Jr., the Chief Operating Officer of Alto Neuroscience, Inc. (ANRO), filed a Form 4 on May 22, 2024, reporting a transaction.
• On May 20, 2024, Hanley acquired options to purchase 188,000 shares of Alto Neuroscience common stock at an exercise price of $12.40 per share.
• These options vest over time, with 25% vesting on May 20, 2025, and the remaining shares vesting monthly over the subsequent 48 months, contingent upon continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard stock option grant to an executive. It's a routine event and doesn't necessarily indicate positive or negative performance.

Positives

• The grant of stock options to the COO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders. This is a standard compensation component.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Biogen, and Gilead Sciences also use stock options to incentivize their executives.
• The vesting schedule of 25% after one year followed by monthly vesting is a common practice.

Stakeholder Impact

• The stock option grant aligns the COO's interests with those of the shareholders, potentially leading to increased shareholder value.

Key Dates